meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - maintenance (M)
2
pancreatic ductal adenocarcinoma
PIK3CA-related overgrowth spectrum
prostate cancer (PC)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab plus SoC
nivolumab based treatment
poly ADP-ribose polymerase (PARP) inhibitor
rucaparib
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs poly ADP-ribose polymerase (PARP) inhibitor
vs rucaparib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Pathology: